8-K: Definitive Healthcare Stockholders Re-Elect Directors, Ratify Auditor, and Approve Executive Compensation at 2025 Annual Meeting
Annual Meeting Results
Definitive Healthcare Corp. announced the successful outcomes of its 2025 Annual Meeting of Stockholders, where all proposals, including the election of Class I directors, ratification of Deloitte & Touche LLP as independent auditor, and advisory approval of executive compensation, were passed.
Summary
- Definitive Healthcare Corp. held its 2025 Annual Meeting of Stockholders on June 5, 2025.
- As of the record date, April 14, 2025, there were 107,962,771 shares of Class A common stock and 38,996,613 shares of Class B common stock issued and outstanding.
- Stockholders elected Kevin Coop, Jason Krantz, and Lauren Young as Class I directors to serve three-year terms expiring at the annual meeting in 2028.
- The election results for directors were: Kevin Coop (118,235,389 For, 3,440,264 Withheld), Jason Krantz (117,507,136 For, 4,168,517 Withheld), and Lauren Young (108,391,016 For, 13,284,637 Withheld). Each nominee had 10,917,987 Broker Non-Votes.
- Stockholders ratified the selection of Deloitte & Touche LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025, with 129,393,656 For, 3,036,651 Against, and 163,334 Abstain.
- Stockholders approved, on a non-binding, advisory basis, the compensation of the company's named executive officers, with 108,597,111 For, 12,910,917 Against, 167,624 Abstain, and 10,917,987 Broker Non-Votes.
Sentiment
Score: 8
Explanation: The successful passage of all proposals at the annual meeting, including the election of directors and ratification of the auditor, indicates stable corporate governance and shareholder alignment with management's recommendations.
Positives
- All company nominees for Class I directors were successfully elected, ensuring board continuity.
- The selection of Deloitte & Touche LLP as the independent auditor for fiscal year 2025 was ratified, maintaining standard financial oversight.
- Executive compensation was approved on an advisory basis, indicating shareholder support for current compensation practices.
Future Outlook
The document does not contain any forward-looking statements or guidance regarding future financial performance or strategic direction.
Industry Context
This 8-K filing details the routine outcomes of an annual stockholder meeting, which is a standard corporate governance event for publicly traded companies across all industries. The results reflect internal company matters rather than broader industry trends.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Class I Director | N/A | Kevin Coop | June 5, 2025 | Elected to a new three-year term by stockholders. |
| Class I Director | N/A | Jason Krantz | June 5, 2025 | Elected to a new three-year term by stockholders. |
| Class I Director | N/A | Lauren Young | June 5, 2025 | Elected to a new three-year term by stockholders. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Election | Stockholders elected Kevin Coop, Jason Krantz, and Lauren Young as Class I directors to serve three-year terms expiring in 2028. | June 5, 2025 | Ensures continuity and stability of the board's Class I directors, maintaining established leadership. |
| Auditor Ratification | Stockholders ratified the selection of Deloitte & Touche LLP as the independent registered public accounting firm for fiscal year 2025. | June 5, 2025 | Confirms the company's independent auditing firm for the current fiscal year, a standard and necessary governance practice for financial transparency. |
| Executive Compensation Advisory Vote | Stockholders approved, on a non-binding, advisory basis, the compensation of the company's named executive officers. | June 5, 2025 | Provides shareholder feedback on executive compensation, indicating general alignment or approval of the current compensation structure. |
Stakeholder Impact
- Shareholders: Confirmed the composition of a class of the board of directors and the independent auditor, and provided advisory approval on executive compensation, reflecting their voice in corporate governance.
- Management: Received shareholder endorsement for their proposed directors and executive compensation structure, indicating a degree of confidence from the ownership base.
Next Steps
- The newly elected Class I directors (Kevin Coop, Jason Krantz, and Lauren Young) will serve their three-year terms until the 2028 annual meeting of stockholders.
- Deloitte & Touche LLP will serve as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025.
Key Dates
| Date | Description |
|---|---|
| April 14, 2025 | Record date for determination of stockholders entitled to vote at the Annual Meeting. |
| April 23, 2025 | Definitive proxy statement filed with the Securities and Exchange Commission. |
| June 5, 2025 | 2025 Annual Meeting of Stockholders held. |
| June 6, 2025 | Date of signing the 8-K report by the Chief Financial Officer. |
| 2028 | Expiration of the three-year term for the newly elected Class I directors. |
Recommendation
holdKeywords
Definitive Healthcare, DH, Annual Meeting, Stockholders, Corporate Governance, Director Election, Auditor Ratification, Executive Compensation, SEC Filing, 8-K
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.